Immunotherapy News and Research

Latest Immunotherapy News and Research

Lilly, ImaginAb partner to study potential novel T-cell-based immuno-oncology therapies

Eli Lilly and Company and ImaginAb Inc. are pleased to announce a preclinical research collaboration to study potential novel T-cell-based immuno-oncology therapies.

13 Oct 2015

ImmunArray launches SLE-key Rule-Out test for lupus patients

Following a limited three-month trial period in which more than one hundred and fifty patients with lupus-like symptoms were tested for the difficult-to-diagnose disease, a new blood test for lupus is being rolled out nationally.

12 Oct 2015

Study looks at survival benefits of surgical resection for melanoma patients with abdominal metastases

Patients with metastatic melanoma who undergo surgery to remove lesions that have spread into the abdomen live more than twice as long as those treated with drug therapy alone, according to novel new research by a North Shore-LIJ Health System cancer surgeon.

12 Oct 2015

FDA awards research grants to boost product development for patients with rare diseases

The U.S. Food and Drug Administration today announced it has awarded 18 new research grants totaling more than $19 million to boost the development of products for patients with rare diseases, which affect the lives of nearly 30 million Americans.

11 Oct 2015

IASLC commends pembrolizumab drug approval for cutting-edge lung cancer treatment

The International Association for the Study of Lung Cancer (IASLC) says the move by the U.S. Food and Drug Administration (FDA) to grant accelerated approval for a cutting-edge lung cancer treatment is a positive step forward that may help many patients improve their survival.

9 Oct 2015

FDA grants accelerated approval for Keytruda to treat patients with advanced NSCLC

The U.S. Food and Drug Administration today granted accelerated approval for Keytruda (pembrolizumab) to treat patients with advanced (metastatic) non-small cell lung cancer (NSCLC) whose disease has progressed after other treatments and with tumors that express a protein called PD-L1. Keytruda is approved for use with a companion diagnostic, the PD-L1 IHC 22C3 pharmDx test, the first test designed to detect PD-L1 expression in non-small cell lung tumors.

9 Oct 2015

Clinical study data on Mallinckrodt's H.P. Acthar Gel to be presented at ACR 2015

Mallinckrodt plc, a leading specialty biopharmaceutical company, today announced that data from a pilot study for its H.P. Acthar Gel (repository corticotropin injection) will be presented at the American College of Rheumatology 2015 Annual Meeting to be held November 7-11 in San Francisco.

8 Oct 2015

Genocea announces positive data in Phase 2 trial evaluating GEN-003 for the treatment of genital herpes

Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, has announced positive results from a planned interim analysis of data collected six months after dosing from its ongoing Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes. At its best performing dose of 60 µg per protein / 75 µg of Matrix-M2TM adjuvant, GEN-003 demonstrated a statistically significant 58 percent reduction from baseline in the viral shedding rate (p < 0.0001), the primary endpoint of the study.

7 Oct 2015

Quest Diagnostics provides PD-L1 IHC 22C3 PharmDx test service for NSCLC patients

Quest Diagnostics, the world’s leading provider of diagnostic information services, today announced that it will provide clinical laboratory testing using the PD-L1 IHC 22C3 PharmDx immunohistochemistry companion diagnostic.

From Quest Diagnostics 7 Oct 2015

OLFUS study supports safety, efficacy of DBV's Viaskin Peanut patch in children with peanut allergy

DBV Technologies, a clinical-stage specialty biopharmaceutical company, today announced that topline findings from the first 12 months of the OLFUS-VIPES study, or OLFUS, support the long-term safety and efficacy of Viaskin Peanut for the treatment of peanut allergy.

7 Oct 2015

Advanced targeted therapies dominate treatment pipeline for colorectal cancer, finds Frost & Sullivan

A vast number and variety of remedies are steadily joining the treatment pipeline for colorectal cancer. High incidence of the disease, unmet clinical needs, and huge commercial potential are attracting drug developers to the market.

1 Oct 2015

Generex agrees to acquire 51% equity interest in Hema Diagnostic Systems

Generex Biotechnology Corporation today announced that it has entered into a non-binding Letter of Intent (LOI) with Hema Diagnostic Systems, LLC (HDS), a Florida company that designs and manufactures proprietary infectious disease detection technologies.

30 Sep 2015

Leading cancer researchers address eight 'big questions'

Leading cancer researchers address eight of the "big questions" facing the field as part of the inaugural issue of Trends in Cancer, published by Cell Press.

30 Sep 2015

Predicting better immunotherapy response, neurological outcomes in adults with autoimmune cerebellar ataxia

While autoimmune cerebellar ataxia (a loss of muscle control coordination) can lead to severe disability with some patients becoming wheelchair-bound, there are factors that may help predict better immunotherapy response, according to the Mayo Clinic study published by JAMA Neurology.

30 Sep 2015

Serologic status and autoimmune cerebellar ataxia type predict treatment response

Patients with autoimmune cerebellar ataxia have better treatment responses and outcomes if they have the nonparaneoplastic form of the condition and are seropositive for neural plasma membrane protein or glutamic acid decarboxylase 65 antibodies, suggests research.

29 Sep 2015

Clinical trial shows nivolumab drug improves overall survival, quality of life in lung cancer patients

An international team of cancer researchers that included UT Southwestern Medical Center physicians announced "game-changing results" using the immunotherapy drug nivolumab to treat certain lung cancers that failed to respond to first-line therapies.

29 Sep 2015

Phase II IMvigor 210 data shows atezolizumab may prevent progression of metastatic urothelial bladder cancer

Data presented today at the 2015 European Cancer Congress (ECC) demonstrates that the investigational immunotherapy atezolizumab may prevent progression of metastatic urothelial bladder cancer (mUBC) in all age groups by 2.1 months.

29 Sep 2015

Combination of two targeted therapies increases survival in advanced melanoma

Latest results from a trial of a combination of two targeted therapies (dabrafenib and trametinib) to treat advanced melanoma have shown that patients are living significantly longer on the combined therapy than patients treated with another drug, vemurafenib, when used alone.

28 Sep 2015

Nivolumab drug significantly prolongs survival in advanced kidney cancer patients

The targeted drug nivolumab significantly prolongs survival in patients with advanced kidney cancer, whose disease has progressed after their first treatment, according to results to be presented at the 2015 European Cancer Congress today (Saturday) and published simultaneously in the New England Journal of Medicine.

26 Sep 2015

Immune checkpoint inhibitor increases survival in patients with advanced renal cell carcinoma

For the first time, an immune checkpoint inhibitor has been proven to increase survival among patients with advanced renal cell carcinoma (RCC), a patient population for whom treatment options are currently limited.

26 Sep 2015

Immunotherapy News and Research

Latest Immunotherapy News and Research

Lilly, ImaginAb partner to study potential novel T-cell-based immuno-oncology therapies

ImmunArray launches SLE-key Rule-Out test for lupus patients

Study looks at survival benefits of surgical resection for melanoma patients with abdominal metastases

FDA awards research grants to boost product development for patients with rare diseases

IASLC commends pembrolizumab drug approval for cutting-edge lung cancer treatment

FDA grants accelerated approval for Keytruda to treat patients with advanced NSCLC

Clinical study data on Mallinckrodt's H.P. Acthar Gel to be presented at ACR 2015

Genocea announces positive data in Phase 2 trial evaluating GEN-003 for the treatment of genital herpes

Quest Diagnostics provides PD-L1 IHC 22C3 PharmDx test service for NSCLC patients

OLFUS study supports safety, efficacy of DBV's Viaskin Peanut patch in children with peanut allergy

Advanced targeted therapies dominate treatment pipeline for colorectal cancer, finds Frost & Sullivan

Generex agrees to acquire 51% equity interest in Hema Diagnostic Systems

Leading cancer researchers address eight 'big questions'

Predicting better immunotherapy response, neurological outcomes in adults with autoimmune cerebellar ataxia

Serologic status and autoimmune cerebellar ataxia type predict treatment response

Clinical trial shows nivolumab drug improves overall survival, quality of life in lung cancer patients

Phase II IMvigor 210 data shows atezolizumab may prevent progression of metastatic urothelial bladder cancer

Combination of two targeted therapies increases survival in advanced melanoma

Nivolumab drug significantly prolongs survival in advanced kidney cancer patients

Immune checkpoint inhibitor increases survival in patients with advanced renal cell carcinoma

Exploring Strategies for Targeting Kinases in Innate Immunity eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Immunotherapy News and Research

Latest Immunotherapy News and Research

Exploring Strategies for Targeting Kinases in Innate Immunity eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Newsletters you may be interested in